New Method Targets Cancerous Tumors Without Harming Healthy Cells
Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects….
The key lies in the acidity level of cells. While normal cells maintain a pH of 7.4 with little variation, cancer cells, expend a great deal of energy as they rapidly proliferate, pumping protons outside and creating an extracellular pH level of 5.5 to 6.5. (The lower the number, the higher the acidity.)…
In addition to targeting cancerous tumors, the couple has discovered a novel delivery agent, a molecular nanosyringe, which can deliver and inject diagnostic or therapeutic agents specifically to cancer cells.
Jaw bone created from stem cells (via BBC News)
Scientists have created part of the jaw joint in the lab using human adult stem cells. They say it is the first time a complex, anatomically-sized bone has been accurately created in this way. It is hoped the technique could be used not only to treat disorders of the specific joint, but more widely to correct problems with other bones too.
New Strategy For Mending Broken Hearts? (via ScienceDaily)
By mimicking the way embryonic stem cells develop into heart muscle in a lab, Duke University bioengineers believe they have taken an important first step toward growing a living “heart patch” to repair heart tissue damaged by disease.
In a series of experiments using mouse embryonic stem cells, the bioengineers used a novel mold of their own design to fashion a three-dimensional “patch” made up of heart muscle cells, known as cardiomyocytes. The new tissue exhibited the two most important attributes of heart muscle cells -– the ability to contract and to conduct electrical impulses. The mold looks much like a piece of Chex cereal in which researchers varied the shape and length of the pores to control the direction and orientation of the growing cells.
The researchers grew the cells in an environment much like that found in natural tissues. They encapsulated the cells within a gel composed of the blood-clotting protein fibrin, which provided mechanical support to the cells, allowing them to form a three-dimensional structure. They also found that the cardiomyocytes flourished only in the presence of a class of “helper” cells known as cardiac fibroblasts, which comprise as much as 60 percent of all cells present in a human heart.
HIV Vaccine Reduces Infection (via BBC News)
An experimental HIV vaccine has for the first time cut the risk of infection, researchers say.
The vaccine - a combination of two earlier experimental vaccines - was given to 16,000 people in Thailand, in the largest ever such vaccine trial. Researchers found that it reduced by nearly a third the risk of contracting HIV, the virus that leads to Aids. It has been hailed as a significant, scientific breakthrough, but a global vaccine is still some way off….
Placebos Are Getting More Effective. Drugmakers Are Desperate to Know Why. (via WIRED)
From 2001 to 2006, the percentage of new products cut from development after Phase II clinical trials, when drugs are first tested against placebo, rose by 20 percent. The failure rate in more extensive Phase III trials increased by 11 percent, mainly due to surprisingly poor showings against placebo. Despite historic levels of industry investment in R&D, the US Food and Drug Administration approved only 19 first-of-their-kind remedies in 2007—the fewest since 1983—and just 24 in 2008. Half of all drugs that fail in late-stage trials drop out of the pipeline due to their inability to beat sugar pills.
The upshot is fewer new medicines available to ailing patients and more financial woes for the beleaguered pharmaceutical industry. Last November, a new type of gene therapy for Parkinson’s disease, championed by the Michael J. Fox Foundation, was abruptly withdrawn from Phase II trials after unexpectedly tanking against placebo. A stem-cell startup called Osiris Therapeutics got a drubbing on Wall Street in March, when it suspended trials of its pill for Crohn’s disease, an intestinal ailment, citing an “unusually high” response to placebo. Two days later, Eli Lilly broke off testing of a much-touted new drug for schizophrenia when volunteers showed double the expected level of placebo response.
It’s not only trials of new drugs that are crossing the futility boundary. Some products that have been on the market for decades, like Prozac, are faltering in more recent follow-up tests. In many cases, these are the compounds that, in the late ’90s, made Big Pharma more profitable than Big Oil. But if these same drugs were vetted now, the FDA might not approve some of them. Two comprehensive analyses of antidepressant trials have uncovered a dramatic increase in placebo response since the 1980s. One estimated that the so-called effect size (a measure of statistical significance) in placebo groups had nearly doubled over that time.
It’s not that the old meds are getting weaker, drug developers say. It’s as if the placebo effect is somehow getting stronger.
The fact that an increasing number of medications are unable to beat sugar pills has thrown the industry into crisis. The stakes could hardly be higher. In today’s economy, the fate of a long-established company can hang on the outcome of a handful of tests.
Why are inert pills suddenly overwhelming promising new drugs and established medicines alike? The reasons are only just beginning to be understood. A network of independent researchers is doggedly uncovering the inner workings—and potential therapeutic applications—of the placebo effect. At the same time, drugmakers are realizing they need to fully understand the mechanisms behind it so they can design trials that differentiate more clearly between the beneficial effects of their products and the body’s innate ability to heal itself. A special task force of the Foundation for the National Institutes of Health is seeking to stem the crisis by quietly undertaking one of the most ambitious data-sharing efforts in the history of the drug industry. After decades in the jungles of fringe science, the placebo effect has become the elephant in the boardroom…..
Over 60 Percent Of All US Bankruptcies Attributable To Medical Problems
In 2007, before the current economic downturn, an American family filed for bankruptcy in the aftermath of illness every 90 seconds; three-quarters of them were insured. Over 60% of all bankruptcies in the United States in 2007 were driven by medical incidents. In an article published in the August 2009 issue of the American Journal of Medicine, the results of the first-ever national random-sample survey of bankruptcy filers shows that illnesses and medical bills contribute to a large and increasing share of bankruptcies. The share of bankruptcies attributable to medical problems rose by 50% between 2001 and 2007…. (continues @ ScienceDaily)
Medical Micro-robots Made As Small As Bacteria
For the first time, ETH Zurich researchers have built micro-robots as small as bacteria. Their purpose is to help cure human beings.
They look like spirals with tiny heads, and screw through the liquid like miniature corkscrews. When moving, they resemble rather ungainly bacteria with long whip-like tails. They can only be observed under a microscope because, at a total length of 25 to 60 µm, they are almost as small as natural flagellated bacteria. Most are between 5 and 15 µm long, a few are more than 20 µm….
The tiny spiral-shaped, nature-mimicking lookalikes of E. coli and similar bacteria. are called “Artificial Bacterial Flagella” (ABFs), the “flagella” referring to their whip-like tails. They were invented, manufactured and enabled to swim in a controllable way….
With the software developed by the group, the ABF can be steered to a specific target by tuning the strength and direction of the rotating magnetic field which is generated by several coils. The ABFs can move forwards and backwards, upwards and downwards, and can also rotate in all directions…. (more @ ScienceDaily)
Ancient Alcoholic Medicines
The earliest sample of human-made medicine was discovered in Egypt:
A team of researchers in the US has discovered traces of a medicinal alcoholic drink in bottles that are more than 5,000 years old. The scientists extracted wine compounds and plant-derived ingredients from a jar taken from the tomb of one of the first pharaohs of Egypt, Scorpion I.
How did they do it?
The team used organic solvents to extract residues from inside the jars. With extremely sensitive chemical techniques, they were then able to separate the different compounds within the residue. The jars tested positive for tartaric acid - a reliable chemical marker for grape and wine in the Middle East. The scientists also found compounds from a number of herbs, some of which have known medicinal properties, and from tree resin. Professor McGovern pointed out that alcoholic drinks would have been ideal for dissolving these plant-derived substances.
Tumblr Powered Bill Israel Designed
